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Abstract Polymerase chain reaction amplification of cDNA
from rat intestine revealed the expression of a novel ABC
transporter, TAPL (TAP-like). Subsequently, the protein
sequence was deduced from the nucleotide sequence of cDNA
carrying the entire coding region. TAPL is transcribed
ubiquitously in various rat tissues. The protein, with 762 amino
acid residues, has potential transmembrane domains, and an
ATP-binding domain in its amino and carboxyl terminal regions,
respectively, and is highly homologous to TAP1 and TAP2
(transporters associated with antigen presentation/processing):
pairwise comparisons with TAPL demonstrated 39 and 41% of
the residues are identical, respectively. These numerical values
are essentially the same as that for TAP1 and TAP2 (39%), and
the hydropathy profiles of TAPL, TAP1 and TAP2 are quite
similar. The similarity among these three proteins suggests that
they could be derived from a common ancestral gene. Further-
more, we found that there is a potential splicing isoform, sharing
the amino terminal 720 amino acid residues of TAPL.
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1. Introduction
Pump ATPases are intrinsic membrane proteins, which
transport solutes across the membranes coupled with ATP
hydrolysis [1]. They are widely distributed in prokaryotes
and eukaryotes, and function in various cellular processes
[2]. The ABC transporters, a family of pump ATPases, trans-
locate a variety of molecules from peptides and proteins to
organic compounds and inorganic ions [3]. Members of this
family have one or two ATP-binding domain(s) comprising
approximately 200 well conserved residues alternating with
one or two transmembrane domains [4].
Recently, the entire yeast genomic structure was determined
[5], and the 29 genes encoding proteins with the ATP-binding
domain (designated to the ATP-binding cassette) character-
istic of ABC transporters were found among approximately
6000 genes [5,6]. Considering the genome size in higher eu-
karyotes [7], it can be assumed that many more genes for
ABC transporters could be found in mammals. Although
the ATP-powered transport mechanism is not well known,
most of the de¢cient functions of mammalian ABC transport-
ers are related to diseases [6]. Furthermore, the clinical
problem of drug resistance is ascribed to the function of
ABC transporters such as P-glycoprotein and the transporters
in human pathogens [6].
The aim of this study is to ¢nd novel mammalian ABC
transporters in the intestine by means of homology cloning,
since we are interested in the secretory functions of the gastro-
intestinal tract [8,9]. cDNA derived from rat intestinal mRNA
was subjected to PCR with degenerate primers for conserved
sequences, Walker A and Walker B motifs [10], of the ATP-
binding domain of ABC transporters. Interestingly, we suc-
ceeded in ¢nding a transcript closely related to TAP1 and
TAP2, both of which participate in peptide transport from
the cytoplasm to the lumen of the endoplasmic reticulum
and the presentation of peptide antigens by MHC class I
[11]. The primary structure of the novel transporter was de-
duced and its characteristics are reported.
2. Materials and methods
2.1. cDNA cloning
Total RNA was extracted from tissues of 5 weeks old Sprague
Dawley rats by the guanidine thiocyanate-CsCl method and then sub-
jected to cDNA synthesis [12]. Degenerate primers 1 and 2 corre-
sponding to the conserved sequences of the ATP-binding cassette
region of ABC transporters [10] were synthesized (Fig. 1A). They
were used to amplify the cassette region of the novel transporter by
means of PCR [13] with cDNA from intestine; the conditions for the
1st and 2nd PCR were 30 cycles of denaturation (94‡C, 1 min), an-
nealing (48‡C, 2 min), and extension (72‡C, 3 min), and 30 cycles of
denaturation (94‡C, 1 min), annealing (55‡C, 2 min), and extension
(72‡C, 3 min), respectively (Fig. 1B).
5P-Upstream and 3P-downstream sequences were ampli¢ed by
RACE using kidney cDNA, since the cDNA in question seems to
be abundant in this organ compared with in intestine. Primers 7^9
and phosphorylated random primers, and primers 13^16 and phos-
phorylated primer 12 were prepared for 5P-RACE using a 5P-Full
RACE Core Set (Takara, Kusatsu, Japan). Primers 3 and 4, and
primers 5 and 6 were prepared for 5P-RACE and 3P-RACE, respec-
tively, using a 5P-RACE System (GIBCO BRL, Tokyo, Japan). cDNA
carrying the entire coding region was obtained by PCR with primer
pairs 11 and 20 then 11 and 21 (Fig. 1B). The PCR conditions for
these experiments were 35 cycles of denaturation (94‡C, 1 min), an-
nealing (55‡C, 2 min), and extension (72‡C, 3 min). In all the PCR,
preheating (94‡C, 3 min) and post-incubation (72‡C, 7 min) were
carried out before and after successive cycle reactions, respectively.
2.2. DNA sequencing
Ampli¢ed DNA was analyzed by agarose gel electrophoresis (1%,
(w/v) Takara Type L03) using TAE bu¡er (1U) [12]. The DNA frag-
ment was ligated to the pCRII vector (Invitrogen, CA, USA) or the
pGEM-T Easy vector (Promega, WI, USA). Both strands of the
cloned DNA were sequenced by the dideoxy chain-termination meth-
od [14] using a Silver Sequence DNA Sequencing System (Promega)
or a Shimadzu DNA Sequencer Model DSQ-1000L.
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2.3. Determination of the tissue distribution of TAPL mRNA and
ampli¢cation of genomic DNA
PCR with primers 3 and 9 was carried out (35 cycles of denatura-
tion (94‡C, 1 min), annealing (60‡C, 2 min), and extension (72‡C,
3 min)). The annealing temperature was reduced to 55‡C for PCR
conditions with primers 10 and 11. The rat L-actin mRNA level
was determined by PCR with primers S and A [15] under the con-
ditions of 35 cycles of denaturation (94‡C, 1 min), annealing (65‡C,
2 min), and extension (72‡C, 3 min). Primer pairs 11 and 20, then 11
and 21 were used as above to amplify the entire coding region of
TAPLa and most of the coding region of TAPLb. After agarose gel
electrophoresis, the speci¢c DNA bands were visualized with ethidium
bromide and then the images were processed with a FluorImager
Model 595 (Molecular Dynamics, CA, USA). Rat genomic DNA
was prepared [12] and partially digested with Sau3AI restriction en-
zyme. The fragments were subjected to PCR with primers 10 and 11
as above.
Fig. 1. Ampli¢cation of cDNA for a novel ABC transporter by PCR. A: Design of degenerate primers for PCR: The nucleotide sequences for
the conserved amino acid sequence motifs (Walker A and Walker B [10]) in the ABC regions of ABC transporters are aligned. Degenerate
primers 1 and 2 for PCR were designed from the aligned sequences; hMDR3 (M23234), mMDR1a (M30697), mMDR1b (M14757), rbCFTR
(U40227), hCFTR (M28668), sCFTR (U20418), hPMP70 (M81182), rPMP70 (D90038/J05256), mPMP68 (X89569), mALDP (Z33637), hALDP
(Z21876), mTAP1 (M55637), mTAP2 (M90459), rTAP1 (X57523) and rTAP2 (X63854). The accession numbers in the GenBank database are
shown in parentheses. The carboxyl terminal ABC regions (C) of MDR and CFTR were chosen in this study. h, human; m, mouse; r, rat; rb,
rabbit; s, sheep. B: Strategy for ampli¢cation of cDNA for TAPL: cDNA was subjected to PCR with primers 1 and 2 shown in A. The ampli-
¢ed 408 bp fragment was sequenced, and 5P-RACE and 3P-RACE were further carried out using the primers indicated by arrows with numeri-
cal values. The resulting clones (N-1, N-2 and N-3 on 5P-RACE, and C-1 and C-2 on 3P-RACE) were sequenced. Finally, primers 11, 20 and
21 were used for PCR ampli¢cation of the cDNA carrying the entire coding region, whose nucleotide sequence was determined. The full length
cDNA is schematically shown in the lower part with a potential initiation codon (ATG) and poly-A additional signal (AATAAA) [21]. Typical
restriction enzyme sites and a poly-A tail are also shown. The dotted box corresponds to the ABC region sandwiched between the Walker A
and Walker B sequence motifs.
C
Fig. 2. Nucleotide sequence of cDNA for rat TAPL with the deduced amino acid sequence. Nucleotide sequences from all the clones shown in
Fig. 1B were combined. Nucleotides are numbered on the right of each line from the ¢rst letter of the initiation codon, and numbers on the
left are those of amino acid residues starting from Met-1. The initiator methionine codon immediately downstream of the in frame termination
codon (underlined) was tentatively assigned. The poly-A additional signal is double-underlined. The primer sequences used for cloning (Fig.
1B) and determination of the tissue distribution of mRNA (Fig. 4) are indicated by arrows over the nucleotide sequence. The 763 bp sequence
missing from clone C-2 (Fig. 1B) is in parentheses. The carboxy terminal residues deduced from clone C-2 are also shown downstream of the
parentheses. Amino acid sequences characteristic of the cluster II ABC transporter subfamily [6] are underlined. The amino acid sequence iden-
tical with that of rat MDR2 [20] is double-underlined.
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2.4. Chemicals
Restriction enzymes were obtained from New England Biolab (MA,
USA), Takara, Toyobo (Osaka, Japan), or Nippon Gene (Toyama,
Japan). T4 DNA ligase was from Takara or Toyobo, and Taq polym-
erase from Nippon Gene or Perkin Elmer (NJ, USA). The PCR prim-
ers were purchased from Sawaday (Tokyo, Japan) or GIBCO BRL.
All other chemicals used were of the highest grade commercially avail-
able.
3. Results
3.1. cDNA cloning of a novel ABC transporter, TAPL
cDNAs derived from rat intestine total RNA were sub-
jected to PCR with degenerate primers (Fig. 1A) for the con-
served ATP-binding cassette region of ABC transporters. The
ampli¢ed DNA fragments of the expected length (about 400
bp) were cloned and sequenced. A novel ATP-binding cassette
sequence (408 bp), which is closely related to that of TAP2
[16], was identi¢ed together with those for MDR1b (one ami-
no terminal cassette sequence and 16 carboxyl terminal cas-
sette sequences) [17]. We named the novel clone TAPL (TAP-
like). We carried out successive PCR using cDNA prepared
from kidney mRNAs followed by ampli¢cation of cDNA
covering the entire coding region of TAPL (Fig. 1B), since
the mRNA level of TAPL seemed to be higher in kidney
than in intestine. The nucleotide and deduced amino acid
sequences of TAPL are shown in Fig. 2.
TAPL, with 762 amino acid residues, is a half size ABC
transporter, whose ATP-binding cassette region is located on
the hydrophilic carboxyl terminal side. The 583Gln-Glu-Pro
and 640Ser-Gly-Gly-Gln motifs in the ABC region, and the
693Ile-Ala-His-Arg-Leu motif downstream of Walker B are
characteristic of the cluster II ABC transporter subfamily [6].
3.2. Similarity of TAPL to TAP
TAPL exhibits signi¢cant homology with TAP1 and TAP2
(Fig. 3). Pairwise comparison demonstrated that 39 and 40%
of the residues are identical, respectively, and 61 and 63% of
the residues are conserved, if we consider the conservative
substitutions [18]. Comparison between TAP1 and TAP2
showed that 39 and 60% residues are identical and conserved,
respectively. Such similarity suggests that the three proteins
might have evolved from a common ancestral gene and might
have closely related functions.
TAPL, TAP1 and TAP2 show similar hydropathy pro¢les,
and seven hydrophobic regions are obvious (not shown), sug-
gesting that their higher ordered structures would also be
correlated if not identical. TAP1 has eight potential trans-
membrane segments, as shown by an expression study on
Escherichia coli [19].
3.3. Presence of isoforms of TAPL
As shown in Fig. 1B, two di¡erent but related clones were
obtained on 3P-RACE. Clone C-1 has an extra 763 bp se-
quence. The two clones have the same nucleotide sequence
Fig. 3. Comparison of the amino acid sequence of TAPLa with those of TAP1 and TAP2. The amino acid sequence of TAPLa was compared
with those of rat TAP1 and TAP2. Identical and conserved residues are denoted by closed and open circles, respectively. The ABC regions are
located between the boxed Walker A and Walker B sequences.
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except that the 763 bp sequence is absent from clone C-2.
They could be derived from potential isoform mRNAs pro-
ducing proteins with di¡erent carboxyl terminal 42 (isoform 1
with 762 residues) and 46 (isoform 2 with 766 residues) amino
acid residues, respectively (Fig. 2). We named these isoforms
TAPLa and TAPLb, respectively. It should be mentioned that
the carboxyl terminal nine residues of TAPLa (Gly718-Gln726),
but not of TAPLb, are identical with those of rat MDR2 [20].
PCR ampli¢cation of rat genomic DNA with primers 10
and 11 (Fig. 1B) revealed only the 911 bp sequence identical
to that of clone C-1 (data not shown), suggesting that clone
C-2 could have been produced through splicing out of the 763
bp sequence from clone C-1 carrying the retained intron [21],
although the potential splicing sequence (CA-AC termini)
does not conform with the GT-AG rule [22]. However, a
splicing sequence with unusual termini such as AT-AC was
recently reported [23].
3.4. Tissue distribution of TAPL mRNAs
To determine the tissue distribution of TAPL, cDNAs pre-
pared from various rat tissues were subjected to PCR. Primers
3 and 9 gave a 366 bp DNA fragment for all tissues examined
(intestine, stomach, kidney, liver, brain, heart, lung, spleen
and testis) (Fig. 4A), which covers Val450-Asp570. The expres-
sion of the two isoforms was also examined using primers 10
and 11. While the 911 bp DNA fragment corresponding to
TAPLa (covering Leu697-end) was reproducibly ampli¢ed, the
148 bp fragment corresponding to TAPLb was not (not
shown). These results suggest that at least TAPLa is ubiqui-
tously transcribed, although the amounts seem to be di¡erent
in di¡erent tissues (Fig. 4A). Consistently, the entire sequence
for TAPLa could be ampli¢ed from all tissues except intestine,
stomach and liver (Fig. 4B). The sequence of TAPLb could
not be obtained from any of the tissues, suggesting that the
transcript of TAPLa could be abundant.
4. Discussion
Our results demonstrate that TAPL, which is closely related
to TAP1 and TAP2, is ubiquitously transcribed in rat tissues.
The sequence similarities of these three ABC transporters sug-
gest that their genes have a common evolutional origin, and
that they presumably have related functions. The TAP1 and
TAP2 proteins hetero-dimerize on the endoplasmic reticulum
membrane with their ABC regions facing cytoplasm, and then
transport peptides onto the luminal side, where the peptides
are bound to MHC class I molecules. Such complexes move
to the plasma membrane and the bound peptides are pre-
sented to killer cell receptors as self and foreign antigens
[11]. Defects in the functions of TAP1 and/or TAP2 cause
human diseases such as Behc°et’s disease [24], multiple sclerosis
[25], and bare lymphocyte syndrome type I [26]. Thus, it
would be of interest to determine whether or not TAPL can
transport peptides, substitute for TAP1 and TAP2, and be
used therapeutically in patients with defects in TAP1 and
TAP2.
It would also be interesting to determine homologous com-
ponents for antigen presentation and peptide transporters
from the view-point of chromosomal localization [27].
TAPL seems to be expressed widely in mammals, since a
search of the EST database revealed that the registered se-
quences for mouse and man exhibited similarities to that of
our TAPL. They had been analyzed in clones from kidney,
and heart and brain, respectively. The fact that the human
TAPL gene is not located on the same chromosome as that
for TAP1 and TAP2 [27,28] could raise the possibility that
TAPL is a peptide transporter not involved in antigen pre-
sentation. However, cells with an impaired TAP function still
express low levels of cell surface MHC class I molecules, sug-
gesting that alternative peptide transporter(s) might partici-
pate in the antigen presentation [29]. Such a TAP-independent
route could be a focus as to the role of TAPL as well as other
ABC transporters with unknown functions.
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